Aktieanalys

Physitrack Q3 2023: Tracking profitable growth - Redeye

Redeye Publicerad: 15 Nov 2023 08:22

Redeye has revised our estimates and fair value range following Physitrack’s Q3 2023 report, which came in close to our forecasts. The report demonstrated growth in Wellness subscription revenues, margin expansion stemming from effective cost management and a 12% year-on-year increase in ARR. However, the strategic focus on higher-margin customers resulted in a slightly softer top-line than anticipated. The adjustments to our fair value range primarily reflect the impact of rising interest rates, leading to a new Base case of SEK38 (SEK41) per share. With the share trading at EV/EBIT 8.5x on ‘24e, we continue to observe a substantial discount compared to its peers.

Länk till analysen i sin helhet: https://www.redeye.se/research/955049/physitrack-q3-2023-tracking-profitable-growth?utm_source=finwire&utm_medium=RSS

Nyheter om Physitrack

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!